CHRS vs MASS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CHRS shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Mixed signals with both opportunities and risks present.
The company exhibits severe financial fragility, highlighted by a Piotroski F-Score of 1/9, indicating a critical lack of fundamental strength. While the balance sheet shows strong liquidity (Current Ratio 4.24) and minimal debt (Debt/Equity 0.03), these are offset by negative revenue growth (-7.70% YoY) and persistent operating losses. Insider sentiment is strongly bearish, with the CEO, CFO, and Directors selling shares amidst a long-term price collapse of 85.9% over five years. The disconnect between the high reported profit margin and the negative operating margin suggests non-operational gains rather than a sustainable business model.
Compare Another Pair
Related Comparisons
CHRS vs MASS: Head-to-Head Comparison
This page compares Coherus Oncology, Inc. (CHRS) and 908 Devices Inc. (MASS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.